Elanco | Products and Services (2024)

FAQs

What company owns Elanco? ›

Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.

Elanco Completes Separation from Lilly

Elanco becomes a fully-independent pure play animal health company.

We have a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. Pet Health: Our pet health products help pets live longer, healthier and more active lives. Our global pet health portfolio is focused on parasiticides, vaccines and therapeutics.

As a result of the news, Elanco's stock price declined over 21%, from $17.97 per share on June 26, 2024 to $14.27 per share on June 27, 2024. BFA Law is investigating whether Elanco and certain of its executives made materially false and/or misleading statements to investors related to the FDA's approval of its drugs.

Enables Elanco to capitalize on emerging trends accelerated by the COVID-19 pandemic, including pet owners' increased desire to access care and products via online, retail, telemedicine, and direct to the doorstep.

Management criteria checks 2/4. Elanco Animal Health's CEO is Jeff Simmons, appointed in Jul 2018, has a tenure of 5.83 years. total yearly compensation is $13.66M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options.

One of the most significant changes Elanco announced was its acquisition of Bayer Animal Health in 2019. The acquisition was completed in August 2020 and catapulted Elanco to the forefront of the animal health industry. Now that the merger is complete, what can investors expect the combined company to do in 2021?

GREENFIELD, Ind. (Inside INdiana Business) — For the first time since becoming an independent company, Greenfield-based Elanco Animal Health (NYSE: ELAN) has been added to the Fortune 1000, a list of the largest U.S. incorporated companies published by Fortune magazine. The company ranks number 768.

Jeff Simmons - Elanco | LinkedIn.

We are providing engineering services for Elanco Animal Health Corporate Headquarters in Indianapolis, Indiana. Elanco, the second-largest independent animal health company in the world, is building a new global headquarters in Indianapolis, Indiana.

Who is the competitor of Elanco? ›

Elanco main competitors are Warner Chilcott, Merck, and U.S. Pharmacopeia. Competitor Summary. See how Elanco compares to its main competitors: Roche Holding AG has the most employees (94,442).

The Company continues to expect positive differentiation related to effectiveness. “We have a robust innovation portfolio and continue to expect to deliver $600 to $700 million of Innovation sales by the end of 2025,” said Jeff Simmons, Elanco President and CEO.

Elanco Animal Health has a consensus rating of Moderate Buy which is based on 5 buy ratings, 3 hold ratings and 1 sell ratings. The average price target for Elanco Animal Health is $18.63.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) ...

Gross profit was $690 million, or 57.3% of revenue on both a reported and adjusted basis in the first quarter of 2024.

Elanco Animal Health Incorporated has closed the acquisition of Bayer Animal Health. The transaction is valued at $6.89 billion. “This milestone is another key step in Elanco's journey," said Jeff Simmons, president and CEO of Elanco.

Elanco U.S. Inc., a subsidiary of Eli Lilly and Company, announced this past October an agreement to acquire Boehringer Ingelheim Vetmedica Inc.'s U.S. feline, canine, and rabies vaccines businesses as well as a fully integrated manufacturing and research and development site for $885 million.

Zoetis Inc.

(/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company.

What do analysts say about Elanco Animal Health? Elanco Animal Health's analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.